tradingkey.logo

Vivos Therapeutics Inc

VVOS
1.970USD
-0.010-0.51%
收盤 12/19, 16:00美東報價延遲15分鐘
16.29M總市值
虧損本益比TTM

Vivos Therapeutics Inc

1.970
-0.010-0.51%

關於 Vivos Therapeutics Inc 公司

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Vivos Therapeutics Inc簡介

公司代碼VVOS
公司名稱Vivos Therapeutics Inc
上市日期Dec 11, 2020
CEOHuntsman (R. Kirk)
員工數量109
證券類型Ordinary Share
年結日Dec 11
公司地址7921 Southpark Plaza,
城市LITTLETON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編80120
電話18669084867
網址https://vivos.com/
公司代碼VVOS
上市日期Dec 11, 2020
CEOHuntsman (R. Kirk)

Vivos Therapeutics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Leonard J. (Lenny) Sokolow, CPA
Mr. Leonard J. (Lenny) Sokolow, CPA
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
其他
293.00K
7.67%
由於公司未披露,未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
其他
293.00K
7.67%

股東統計

更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
其他
73.37%
持股股東
持股股東
佔比
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
其他
73.37%
股東類型
持股股東
佔比
Individual Investor
16.39%
Corporation
8.27%
Hedge Fund
5.48%
Investment Advisor
4.48%
Investment Advisor/Hedge Fund
1.08%
Venture Capital
0.92%
其他
63.38%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
53
815.76K
10.87%
-21.74K
2025Q2
60
2.22M
33.10%
+944.35K
2025Q1
65
1.44M
22.49%
+733.38K
2024Q4
63
1.28M
22.00%
+869.59K
2024Q3
68
786.28K
18.32%
+305.75K
2024Q2
66
387.48K
12.85%
-179.65K
2024Q1
67
465.07K
19.33%
-62.17K
2023Q4
69
458.43K
25.00%
-105.78K
2023Q3
76
380.33K
31.77%
-57.99K
2023Q2
78
390.56K
32.63%
-94.20K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Skaff (Michael C.)
828.00K
11.03%
+828.00K
--
Jun 09, 2025
Luo (Dawei)
572.02K
7.62%
+572.02K
--
Jul 08, 2025
V-CO Investors, L.L.C.
514.50K
6.86%
--
--
Jun 09, 2025
Armistice Capital LLC
250.28K
3.33%
+250.28K
--
Sep 30, 2024
Intracoastal Capital, L.L.C.
228.61K
3.05%
+228.61K
--
Dec 30, 2024
The Vanguard Group, Inc.
42.63K
0.57%
--
--
Jun 30, 2025
Ionic Ventures LLC
83.00K
1.11%
+83.00K
--
Sep 30, 2024
Huntsman (Ronald Kirk)
73.06K
0.97%
--
--
Sep 08, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
公告日期
類型
比率
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1

常見問題

Vivos Therapeutics Inc的前五大股東是誰?

Vivos Therapeutics Inc的前五大股東如下:
Skaff (Michael C.)
持有股份:828.00K
佔總股份比例:11.03%。
Luo (Dawei)
持有股份:572.02K
佔總股份比例:7.62%。
V-CO Investors, L.L.C.
持有股份:514.50K
佔總股份比例:6.86%。
Armistice Capital LLC
持有股份:250.28K
佔總股份比例:3.33%。
Intracoastal Capital, L.L.C.
持有股份:228.61K
佔總股份比例:3.05%。

Vivos Therapeutics Inc的前三大股東類型是什麼?

Vivos Therapeutics Inc 的前三大股東類型分別是:
Skaff (Michael C.)
Luo (Dawei)
V-CO Investors, L.L.C.

有多少機構持有Vivos Therapeutics Inc(VVOS)的股份?

截至2025Q3,共有53家機構持有Vivos Therapeutics Inc的股份,合計持有的股份價值約為815.76K,占公司總股份的10.87% 。與2025Q2相比,機構持股有所增加,增幅為-22.23%。

哪個業務部門對Vivos Therapeutics Inc的收入貢獻最大?

在FY2025Q2,Appliance sales to integrated providers業務部門對Vivos Therapeutics Inc的收入貢獻最大,創收1.03M,占總收入的26.91% 。
KeyAI